AKT1 and inflammatory breast carcinoma: Further, alterations private to the metastasis compared to the paired primary ILC (of 32 patients) were seen in such genes, including mutations in CDH1, ARID1A, ERBB2, ESR1, AKT1, GATA3, and NF1; copy number deletions for MAP2K4, NCOR1, TP53, PTEN, and AKT1; and amplifications of CCND1 and CCNE1. ILCs from EuroILC and MSK-IMPACT were in general similar, whilst there was an increase in CDH1, ERBB2, FOXA1, and TBX3 mutations and fewer TP53 mutations between ILC and IBC-NST metastases.